-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Sangamo Therapeutics, Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2014 to 2024.
- Sangamo Therapeutics, Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -$49 M, a 330% decline year-over-year.
- Sangamo Therapeutics, Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was -$333 M, a 163% decline year-over-year.
- Sangamo Therapeutics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$263 M, a 37% decline from 2022.
- Sangamo Therapeutics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$192 M, a 7.79% decline from 2021.
- Sangamo Therapeutics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$178 M, a 47.4% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)